医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Astellas Awards Accenture Contract to Standardize Global IT Operations

2013年05月08日 PM02:25
このエントリーをはてなブックマークに追加


 

TOKYO & NEW YORK

Accenture (NYSE: ACN) has signed an eight-year application outsourcing agreement with Astellas Pharma Inc. (TSE:4503, “Astellas”). As part of the contract, Accenture will deliver application development and maintenance services to the leading pharmaceutical company, which researches, develops and manufactures prescription drugs.

Accenture will help modernize and standardize Astellas’ core business systems, such as accounting, production management, purchasing and supply chain management in its Japan, North America and European regions. Accenture will leverage its Global Delivery Network locations in India, China and Brazil to support the engagement.

Astellas’ objective for the engagement is to prepare a foundation for accelerated globalization of its business. The company plans to do so by working with Accenture to standardize its global information technology (IT) operations. This will help Astellas improve both the efficiency and effectiveness of its IT function and increase its focus on driving innovation into its global business model to improve competitive positioning.

“Astellas is a leader in driving globalization and serves as a model for many large Japanese multinational companies trying to globalize their operations in the marketplace,” said Todor Radmilovich, Accenture managing director based in Japan. “Accenture is proud to assist Astellas in its efforts by utilizing our deep industry knowledge and skills, globally industrialized IT processes and assets, and passion for driving change and improvements. We look forward to working with Astellas on an exciting transformation journey and helping the company achieve its globalization goals.”

Learn more about Accenture’s Life Sciences practice.

About Accenture

Accenture is a global management consulting, technology services and outsourcing company, with 261,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US $27.9 billion for the fiscal year ended Aug. 31, 2012. Its home page is www.accenture.com.

CONTACT

Accenture Japan Ltd.
Ken Kanda, + 81 45 330 7377
+ 81 80-3723
9580 (mobile)
kentaro.kanda@accenture.com
or
Accenture
Cam
Granstra, + 312-693-5992
cameria.l.granstra@accenture.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続